Abstract
This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulatory effects may lead to improvement of symptoms and echocardiographic markers of cardiac contractile performance in these patients.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Adjuvants, Immunologic / pharmacology
-
Adjuvants, Immunologic / therapeutic use*
-
Aged
-
Cardiotonic Agents / administration & dosage
-
Cardiotonic Agents / pharmacology
-
Cardiotonic Agents / therapeutic use*
-
Fas Ligand Protein
-
Female
-
Heart Failure / blood
-
Heart Failure / drug therapy*
-
Humans
-
Hydrazones / administration & dosage
-
Hydrazones / pharmacology
-
Hydrazones / therapeutic use*
-
Infusions, Intravenous
-
Interleukin-6 / blood*
-
Male
-
Membrane Glycoproteins / blood
-
Membrane Glycoproteins / drug effects*
-
Pyridazines / administration & dosage
-
Pyridazines / pharmacology
-
Pyridazines / therapeutic use*
-
Simendan
-
Ventricular Function, Left / drug effects
Substances
-
Adjuvants, Immunologic
-
Cardiotonic Agents
-
FASLG protein, human
-
Fas Ligand Protein
-
Hydrazones
-
Interleukin-6
-
Membrane Glycoproteins
-
Pyridazines
-
Simendan